Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
[25] RCT Crossover design	24 people	Proportion of people reporting one or more adverse effect 24/24 (100%) with high-dose mirtazapine 18/24 (75%) with placebo	P = 0.39		Not significant
[23] RCT 4-armed trial	93 people	Proportion of people reporting one or more adverse effect 14/23 (61%) with low-dose mirtazapine 10/23 (43%) with placebo	Significance not assessed